Pivotal readout

Henlius Achieves Full Reimbursement Coverage

China's 2026 national reimbursement list includes all five approved indications for Henlius's serplulimab and adds first-line reimbursement for fuviciclib in HR-positive, HER2-negative advanced breast cancer. All eight Henlius products marketed in China are now included in the national reimbursement list, which takes effect on January 1, 2027. The company reports that long-term follow-up from a phase 3 fuviciclib study showed a 33% lower risk of death versus placebo.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call